Anti-angiogenesis therapy has benefited many patients with cancer; however, insufficient efficacy, intrinsic refractoriness, and development of resistance have significantly reduced the therapeutic benefits of these therapies. Various hypotheses were proposed to explain the resistance associated with the anti-angiogenesis therapies, none was proven adequately to explain the apparent refractoriness and development of resistance. There is also a major gap in our understanding of the molecular determinants of development of resistance and refractoriness to anti- angiogenesis agents. Given that a significant research and financial efforts were spent on the development of anti- angiogenesis drugs, understanding the modes and mechanisms of resistance to anti-angiogenesis warrants further investigation. We have recently identified lysine methylation, a novel and previously unrecognized posttranslational modification that promotes kinase activation of VEGFR-2. Preventing methylation of VEGFR-2 on a specific lysine 1041 (K1041) residue inhibited VEGFR-2 mediated angiogenesis in cell culture, zebrafish and tumor growth in mouse. Our preliminary data demonstrates that the methylation of VEGFR-2 is associated with refractoriness and development of resistance to certain cancer therapies. Based on our recent published and data presented in the current application, we propose to investigate role of methylation of VEGFR-2 in de novo resistance to anti- angiogenesis therapy. The following specific aims are proposed to test our hypothesis. (A) Examine the hypothesis that methylation of VEGFR-2 is responsible for refractoriness and development of resistance to certain cancer therapies. Various mouse and zebrafish models will be used to examine role of methylation of VEGFR-2 resistance to anti-angiogenesis therapies. (B)Determine methylation status of VEGFR-2 in human colorectal cancer and correlate with responsiveness to angiogenesis inhibitors. There is an unmet need for effective anti-angiogenesis therapies. Establishing a link between methylation of VEGFR-2 and resistance/refractoriness to anti-angiogenic therapies could lead to a new class of cancer therapy and could overcome refractoriness and resistance to angiogenesis therapies.

Public Health Relevance

Angiogenesis inhibitors targeting the VEGF signaling pathway have been FDA approved for various cancer treatments. Although beneficial, patients inevitably develop resistance and often fail to demonstrate significantly better overall survival. Interfering with the methylation of VEGFR-2 may overcome refractoriness and resistance to certain class of anti- cancer drugs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Exploratory/Developmental Grants (R21)
Project #
1R21CA191970-01
Application #
8814348
Study Section
Special Emphasis Panel (ZCA1-SRB-1 (O1))
Program Officer
Forry, Suzanne L
Project Start
2014-12-08
Project End
2016-11-30
Budget Start
2014-12-08
Budget End
2015-11-30
Support Year
1
Fiscal Year
2015
Total Cost
$213,629
Indirect Cost
$83,129
Name
Boston University
Department
Pathology
Type
Schools of Medicine
DUNS #
604483045
City
Boston
State
MA
Country
United States
Zip Code
02118
Ho, Rachel Xi-Yeen; Meyer, Rosana D; Chandler, Kevin B et al. (2018) MINAR1 is a Notch2-binding protein that inhibits angiogenesis and breast cancer growth. J Mol Cell Biol 10:195-204
Chandler, Kevin Brown; Leon, Deborah R; Meyer, Rosana D et al. (2017) Site-Specific N-Glycosylation of Endothelial Cell Receptor Tyrosine Kinase VEGFR-2. J Proteome Res 16:677-688
Rahimi, Nader (2017) Defenders and Challengers of Endothelial Barrier Function. Front Immunol 8:1847
Woolf, N; Pearson, B E; Bondzie, P A et al. (2017) Targeting tumor multicellular aggregation through IGPR-1 inhibits colon cancer growth and improves chemotherapy. Oncogenesis 6:e378
Maghsoudlou, Armin; Meyer, Rosana D; Rezazadeh, Kobra et al. (2016) RNF121 Inhibits Angiogenic Growth Factor Signaling by Restricting Cell Surface Expression of VEGFR-2. Traffic 17:289-300
Huang, Zhifeng; Marsiglia, William M; Basu Roy, Upal et al. (2016) Two FGF Receptor Kinase Molecules Act in Concert to Recruit and Transphosphorylate Phospholipase C?. Mol Cell 61:98-110
Shashar, Moshe; Siwak, Jamaica; Tapan, Umit et al. (2016) c-Cbl mediates the degradation of tumorigenic nuclear ?-catenin contributing to the heterogeneity in Wnt activity in colorectal tumors. Oncotarget 7:71136-71150
Wang, Yun Hwa Walter; Meyer, Rosana D; Bondzie, Philip A et al. (2016) IGPR-1 Is Required for Endothelial Cell-Cell Adhesion and Barrier Function. J Mol Biol 428:5019-5033
Srinivasan, Srimathi; Chitalia, Vipul; Meyer, Rosana D et al. (2015) Hypoxia-induced expression of phosducin-like 3 regulates expression of VEGFR-2 and promotes angiogenesis. Angiogenesis 18:449-62
Shivanna, Sowmya; Harrold, Itrat; Shashar, Moshe et al. (2015) The c-Cbl ubiquitin ligase regulates nuclear ?-catenin and angiogenesis by its tyrosine phosphorylation mediated through the Wnt signaling pathway. J Biol Chem 290:12537-46

Showing the most recent 10 out of 11 publications